Semaglutide 1 mg for weight loss: what to expect at this stage of treatment

You're at 1 mg and wondering if something's gone wrong

It happens often. You've been injecting for a couple of months, you're at 1 mg, and you're comparing notes (online, with a friend, somewhere) and it sounds like other people are already losing significant weight. You feel a bit flat about it. That's worth acknowledging, because the early stages of any weight-loss treatment can feel like you're treading water when you expected to be swimming.

Here's what's actually happening at 1 mg. Wegovy's titration schedule runs 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and then 2.4 mg, held at each level for roughly four weeks under prescriber guidance. The 1 mg step is the third rung, and its primary job is the same as the two before it: keeping your gut comfortable enough to reach the doses where the clinical data on weight loss was gathered. The full Wegovy dose schedule explains each stage in more detail. The medicine is working at 1 mg (you're not stuck) but you haven't reached the therapeutic target yet. Most people do notice reduced appetite at this stage; some notice more than others, and individual responses vary considerably.

What you should not do is try to speed things up yourself. The titration pace is there for a reason: GI side effects like nausea, diarrhoea and constipation tend to be more manageable when the dose climbs gradually, and a prescriber will consider whether you're ready to move on at each review. If you feel your titration feels unusually slow, that's a conversation to have with your clinical team, not a reason to skip a step.

What the trial evidence says, and what it doesn't say about 1 mg specifically

The landmark STEP 1 trial, published in the New England Journal of Medicine, showed an average weight reduction of around 15% over 68 weeks in adults without diabetes, using 2.4 mg semaglutide weekly. That figure is the one most associated with Wegovy, and rightly so, it's the maintenance dose the trial was built around.

There's no comparable standalone trial for 1 mg in the weight-management context, because 1 mg was never intended to be a stopping point. The figure to keep in mind is that the full effect takes time, and the titration period is part of that time, not wasted weeks, but the foundation on which maintenance-dose results are built. People who reach 2.4 mg having titrated carefully tend to tolerate it better than those who rush. If you want to understand how semaglutide dosing for weight loss works as a whole, that page covers the clinical rationale in more depth.

The newer 7.2 mg single-dose pen, approved by the MHRA in April 2026, represents a further development for people who tolerate and respond to the standard titration but want to push further. That's a long way from 1 mg, and it's worth keeping perspective: right now, you are exactly where the schedule says you should be.

Side effects at 1 mg: what's typical at this point

Gastrointestinal effects are the most commonly reported at every stage of semaglutide treatment. At 1 mg, nausea, loose stools, constipation and reflux are the ones patients mention most. They tend to be most noticeable in the first week after a dose increase and often settle as your body adjusts. Fatigue and mild headache crop up too, though less frequently.

A few things are worth knowing about managing this stage. Eating smaller portions, avoiding very fatty or rich food, and staying well hydrated all help. The side effects at 1 mg are generally similar in character to what you may have noticed at 0.5 mg, sometimes slightly more pronounced. If you're finding them hard to manage, tell your prescriber before the next planned dose increase, it's reasonable to hold at 1 mg a little longer if your body needs it.

If you develop severe, persistent stomach pain that reaches through to your back, that's a symptom to take seriously and seek medical attention for promptly. The MHRA has highlighted acute pancreatitis as a known (though infrequent) side effect of GLP-1 medicines, and it's one that warrants urgent assessment rather than a wait-and-see approach. Any suspected side effect can be reported at the MHRA's Yellow Card scheme.

Where 1 mg sits relative to your next steps

After 1 mg, the typical next step is 1.7 mg, still not the maintenance dose, but meaningfully closer. From there, most people move to 2.4 mg, which is where the licensed weight-management dose sits and where the clinical trial results were recorded. For a closer look at that dose, our page on 2.4 mg semaglutide and weight loss covers what the evidence shows at that level.

There's also a separate page on the 7.2 mg semaglutide option for those curious about whether higher doses are relevant to them, though that conversation is firmly one for a prescriber, and it's not the right starting point for someone who's just reached 1 mg.

In terms of cost context, private Wegovy treatment is priced by dose and provider and typically changes as you move up the schedule. If you're weighing that up, our treatment overview page sets out what's included in a single transparent price at nume, with no subscription and no hidden fees. That page also explains how to check any online pharmacy on the GPhC register before committing to treatment anywhere.

If you're at 1 mg and simply want a prescriber to review where you are, what's normal at this point, and whether your progress is on track, that's exactly the kind of conversation our clinical team has regularly. A consultation is free, and a named GPhC-registered prescriber reads your answers, not software. If you're using a compounded or reconstituted product rather than a pre-filled pen, our guide on mixing 5mg semaglutide walks through the preparation steps in detail. You can also read more about what to expect from the semaglutide 2 mg dose for weight loss as your titration progresses toward the maintenance level. Start your free consultation when you're ready.